SXTC Company Profile and Key Details

China SXT Pharmaceuticals, Inc. generated EPS of -$35.49 over the past year. Five-year average earnings growth is 79.65%.

SXTC has shown weak momentum, losing -32.61% over the past week and -93.1% over the past quarter, though year-to-date performance is down -94.01%. Short-term trend indicators are bullishly aligned (SMA20 -90.57%, SMA50 -97.02%, SMA200 -97.97%). The stock’s 14-day RSI is 24.4 (weak momentum), while the ATR of 29.82 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -99.61% below its high and over 13.11% above its low. Average 10-day trading volume of 977.35 thousand shares is significantly above the 3-month average of 158.32 thousand, indicating heightened recent market interest.

China SXT Pharmaceuticals, Inc. has 116.03 million shares outstanding. The public float is 75.03 million shares, elevated short interest at 0.06% of float. This equals 75.18 thousand shares. The short ratio is 1.15 days. Institutional investors hold 0.41% of the float. Insiders own 35.33%.

China SXT Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $9.13. This means the shares are trading below this model’s fair value.

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) closed at $4.53 USD, gaining $4.49 (10,410.44%) from the previous close of $0.04. The stock is currently mid-range between its 52-week high and low $4.00 and $1.18 thousand. With a market capitalization of about $579.96 million, China SXT Pharmaceuticals, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.68). Key stats such as the average daily volume over the past year has been around 160.84 thousand shares, trading with heavier-than-usual volume. Headquartered in Taizhou, None, China SXT Pharmaceuticals, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Feng Zhou, the company employs approximately 75 people and listed since January 04, 2019. China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China.

China SXT Pharmaceuticals, Inc. trades at a P/E ratio of -3.77, slightly below the S&P 500 average, with a price-to-sales ratio of 432.5 and a price-to-book ratio of 0.54 suggesting the stock is closer to book value. The P/FCF stands at -343.7, also below market averages.

Our AI price prediction model suggests that China SXT Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -100.0%, with price expected at $0.00 by February 16, 2026, within a range of $0.00 to $0.05 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by May 01, 2026, with a range of $0.00 to $0.14. 1-Year Outlook: Projected loss of -97.57%, with price at $0.11 by February 02, 2027, within a range of $0.00 to $1.09.

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) shares are down -94.01% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows China SXT Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -3.77. Our AI forecast model points to short-term weakness (-100.0% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-97.57% over one year), with expected trading ranges indicating moderate volatility.